Just published in The Journal of Liquid Biopsy Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic
Introducing a novel liquid biopsy approach combining cfRNA and cfDNA sequencing. Our findings demonstrate superior mutation detection with cfRNA, while cfDNA excels in identifying chromosomal aberrations. Elevated cfRNA biomarkers correlate with tumor types, aiding diagnosis. Machine learning predicts cancer types accurately. Host immune response analysis through cfRNA ratios reveals distinct patterns in cancer patients. This integrated approach holds promise for predicting genomic abnormalities and cancer diagnosis
